<b>Background/Objectives</b>: KRAS G12D is one of the most frequent oncogenic mutations in pancreatic ductal adenocarcinoma (PDAC) and remains challenging to target because of its limited druggable binding pockets. Here, KRAS is linked to pancreatic ductal adenocarcinoma.